Ponalrestat

Ponalrestat (ICI 128436) is an orally active, selective and noncompetitive aldose reductase (AKR1B1; ALR) inhibitor. Ponalrestat selectively inhibits ALR2 (Ki=7.7 nM) over ALR1 (Ki=60 μM) . Ponalrestat inhibits the conversion of glucose to sorbitol[1][2][3].

Product Specifications

CAS Number

[72702-95-5]

Product Name Alternative

ICI 128436

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Aldose Reductase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/ponalrestat.html

Concentration

10mM

Purity

99.51

Solubility

DMSO : 62.5 mg/mL (ultrasonic)

Smiles

OC(CC(C1=C2C=CC=C1)=NN(CC3=C(C=C(Br)C=C3)F)C2=O)=O

Molecular Formula

C17H12BrFN2O3

Molecular Weight

391.19

Precautions

H302, H315, H319, H335

References & Citations

[1]Ward WH, et al. Ponalrestat: a potent and specific inhibitor of aldose reductase. Biochem Pharmacol. 1990 Jan 15;39 (2) :337-46.|[2]Bresson E, et al. The human aldose reductase AKR1B1 qualifies as the primary prostaglandin F synthase in the endometrium. J Clin Endocrinol Metab. 2011 Jan;96 (1) :210-9.|[3]Calcutt NA, et al. Prevention of sensory disorders in diabetic Sprague-Dawley rats by aldose reductase inhibition or treatment with ciliary neurotrophic factor. Diabetologia. 2004 Apr;47 (4) :718-24.